Multiple potential clinical benefits for 1α,25-dihydroxyvitamin D3 analogs in kidney transplant recipients

Matthew D. Griffin, Rajiv Kumar

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Therapeutic trials of 1α,25(OH)2D3 and related synthetic analogs are merited in diverse clinical fields, including treatment or prevention of bone disease, cancer, immune-mediated diseases, cardiovascular diseases, and prostatic hypertrophy. Potential difficulties of carrying out such trials successfully, include experimental data suggesting relatively modest therapeutic effects of 1α,25(OH)2D3 analogs as stand-alone intervention and the likely requirement for large study group size and lengthy follow-up periods, if individual prophylactic effects are to be proven. Thus, it may be wise to identify patient groups with multiple potential benefits, accelerated disease risks, and the possibility for exploring synergistic pharmacological effects, in whom to carry out clinical trials of 1α,25(OH)2D3 analogs. With this consideration in mind, the suitability of kidney transplant recipients for such studies is discussed. Although, highly effective in reversing end-stage renal disease, kidney transplantation continues to be limited by heightened risk of osteoporosis, persistent hyperparathyroidism, acute and chronic immunological injury, new cancer diagnosis, and cardiovascular events. In addition, kidney transplant recipients generally receive multiple immunosuppressants with a high prevalence of medication-related toxicities. Finally, it is pointed out that clinical trials carried out in organ transplant recipients provide a unique opportunity for longitudinal comparison of target tissue structural and gene expression profiles among treated and control patient groups. It is proposed that addition of a 1α,25(OH)2D3 analog to conventional post-kidney transplant medication regimens is likely to be associated with measurable effects to prevent or retard multiple important complications and that this patient group is especially suitable for carrying out clinical trials of these compounds.

Original languageEnglish (US)
Pages (from-to)213-218
Number of pages6
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume97
Issue number1-2
DOIs
StatePublished - Oct 2005

Fingerprint

Transplants
Calcitriol
Clinical Trials
Kidney
Bone Neoplasms
Hyperparathyroidism
Bone Diseases
Immune System Diseases
Prostatic Hyperplasia
Therapeutic Uses
Immunosuppressive Agents
Transcriptome
Kidney Transplantation
Osteoporosis
Chronic Kidney Failure
Cardiovascular Diseases
Pharmacology
Control Groups
Gene expression
Wounds and Injuries

Keywords

  • 1,25-Dihydroxyvitamin D
  • Clinical trials
  • Renal transplantation

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Multiple potential clinical benefits for 1α,25-dihydroxyvitamin D3 analogs in kidney transplant recipients. / Griffin, Matthew D.; Kumar, Rajiv.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 97, No. 1-2, 10.2005, p. 213-218.

Research output: Contribution to journalArticle

@article{6a569232de7e47e39d9257a5b953fe75,
title = "Multiple potential clinical benefits for 1α,25-dihydroxyvitamin D3 analogs in kidney transplant recipients",
abstract = "Therapeutic trials of 1α,25(OH)2D3 and related synthetic analogs are merited in diverse clinical fields, including treatment or prevention of bone disease, cancer, immune-mediated diseases, cardiovascular diseases, and prostatic hypertrophy. Potential difficulties of carrying out such trials successfully, include experimental data suggesting relatively modest therapeutic effects of 1α,25(OH)2D3 analogs as stand-alone intervention and the likely requirement for large study group size and lengthy follow-up periods, if individual prophylactic effects are to be proven. Thus, it may be wise to identify patient groups with multiple potential benefits, accelerated disease risks, and the possibility for exploring synergistic pharmacological effects, in whom to carry out clinical trials of 1α,25(OH)2D3 analogs. With this consideration in mind, the suitability of kidney transplant recipients for such studies is discussed. Although, highly effective in reversing end-stage renal disease, kidney transplantation continues to be limited by heightened risk of osteoporosis, persistent hyperparathyroidism, acute and chronic immunological injury, new cancer diagnosis, and cardiovascular events. In addition, kidney transplant recipients generally receive multiple immunosuppressants with a high prevalence of medication-related toxicities. Finally, it is pointed out that clinical trials carried out in organ transplant recipients provide a unique opportunity for longitudinal comparison of target tissue structural and gene expression profiles among treated and control patient groups. It is proposed that addition of a 1α,25(OH)2D3 analog to conventional post-kidney transplant medication regimens is likely to be associated with measurable effects to prevent or retard multiple important complications and that this patient group is especially suitable for carrying out clinical trials of these compounds.",
keywords = "1,25-Dihydroxyvitamin D, Clinical trials, Renal transplantation",
author = "Griffin, {Matthew D.} and Rajiv Kumar",
year = "2005",
month = "10",
doi = "10.1016/j.jsbmb.2005.06.014",
language = "English (US)",
volume = "97",
pages = "213--218",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - Multiple potential clinical benefits for 1α,25-dihydroxyvitamin D3 analogs in kidney transplant recipients

AU - Griffin, Matthew D.

AU - Kumar, Rajiv

PY - 2005/10

Y1 - 2005/10

N2 - Therapeutic trials of 1α,25(OH)2D3 and related synthetic analogs are merited in diverse clinical fields, including treatment or prevention of bone disease, cancer, immune-mediated diseases, cardiovascular diseases, and prostatic hypertrophy. Potential difficulties of carrying out such trials successfully, include experimental data suggesting relatively modest therapeutic effects of 1α,25(OH)2D3 analogs as stand-alone intervention and the likely requirement for large study group size and lengthy follow-up periods, if individual prophylactic effects are to be proven. Thus, it may be wise to identify patient groups with multiple potential benefits, accelerated disease risks, and the possibility for exploring synergistic pharmacological effects, in whom to carry out clinical trials of 1α,25(OH)2D3 analogs. With this consideration in mind, the suitability of kidney transplant recipients for such studies is discussed. Although, highly effective in reversing end-stage renal disease, kidney transplantation continues to be limited by heightened risk of osteoporosis, persistent hyperparathyroidism, acute and chronic immunological injury, new cancer diagnosis, and cardiovascular events. In addition, kidney transplant recipients generally receive multiple immunosuppressants with a high prevalence of medication-related toxicities. Finally, it is pointed out that clinical trials carried out in organ transplant recipients provide a unique opportunity for longitudinal comparison of target tissue structural and gene expression profiles among treated and control patient groups. It is proposed that addition of a 1α,25(OH)2D3 analog to conventional post-kidney transplant medication regimens is likely to be associated with measurable effects to prevent or retard multiple important complications and that this patient group is especially suitable for carrying out clinical trials of these compounds.

AB - Therapeutic trials of 1α,25(OH)2D3 and related synthetic analogs are merited in diverse clinical fields, including treatment or prevention of bone disease, cancer, immune-mediated diseases, cardiovascular diseases, and prostatic hypertrophy. Potential difficulties of carrying out such trials successfully, include experimental data suggesting relatively modest therapeutic effects of 1α,25(OH)2D3 analogs as stand-alone intervention and the likely requirement for large study group size and lengthy follow-up periods, if individual prophylactic effects are to be proven. Thus, it may be wise to identify patient groups with multiple potential benefits, accelerated disease risks, and the possibility for exploring synergistic pharmacological effects, in whom to carry out clinical trials of 1α,25(OH)2D3 analogs. With this consideration in mind, the suitability of kidney transplant recipients for such studies is discussed. Although, highly effective in reversing end-stage renal disease, kidney transplantation continues to be limited by heightened risk of osteoporosis, persistent hyperparathyroidism, acute and chronic immunological injury, new cancer diagnosis, and cardiovascular events. In addition, kidney transplant recipients generally receive multiple immunosuppressants with a high prevalence of medication-related toxicities. Finally, it is pointed out that clinical trials carried out in organ transplant recipients provide a unique opportunity for longitudinal comparison of target tissue structural and gene expression profiles among treated and control patient groups. It is proposed that addition of a 1α,25(OH)2D3 analog to conventional post-kidney transplant medication regimens is likely to be associated with measurable effects to prevent or retard multiple important complications and that this patient group is especially suitable for carrying out clinical trials of these compounds.

KW - 1,25-Dihydroxyvitamin D

KW - Clinical trials

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=27544437477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544437477&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2005.06.014

DO - 10.1016/j.jsbmb.2005.06.014

M3 - Article

VL - 97

SP - 213

EP - 218

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-2

ER -